LN-145/LN-144
Phase 1Biologic
LN-145/LN-144 is one of 28 biologic programs targeting Adolescent. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Adolescent
#DrugCompanyPhaseTrials
1Zoloft
VViatris Specialty LLC
Approved
Abilify
OtsukaApproved
Fanapt
VVanda Pharmaceuticals
Approved
Sunlenca
GileadPhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Brintellix
TakedaPhase 2
Cymbalta
Jazz PharmaceuticalsPhase 2
Camptosar
PfizerPhase 2
Valdoxan
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LN-145/LN-144. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- IIovance Biotherapeutics, Inc.